Neogen (NEOG) Q1 2025 Earnings Call Transcript

Neogen reported fiscal Q1 revenue of $217M with core revenue down 1% and a 390bp FX headwind; Food Safety revenue fell 4% to $159M while Animal Safety core revenue declined 8%. Gross margin declined 260bps to 48.4% (adjusted decline 90bps), adjusted EBITDA was $44M (20.1%, down 280bps) and adjusted EPS was $0.07 vs $0.11 a year ago. Management maintained full-year guidance, expects roughly 3x net leverage at year-end with $900M gross debt and $120M cash, said ERP/shipping issues are resolved with normalized production targeted by Q3, but cited an ~$8M share-loss headwind and ongoing uncertainty around the timing and pace of share recovery.

Analysis

Neogen's path back to sustainable growth is primarily an operations-credibility story: market share in high-margin testing (Petrifilm and adjacent automation) will re-accelerate only after customers observe sustained, repeatable supply and reduced distribution friction. That dynamic creates a measurable two- to four-quarter catalyst window — if the company can show sequential improvement in fill rates and unit economics over that period, the revenue cadence should inflect faster than headline organic growth because testing spends are sticky once re-contracted.

Second-order winners include automation and consumables partners that benefit from increased throughput (readers/feeders) and distributors whose unit margins expand with higher repeatable order frequency; losers are competitors and contract manufacturers that captured temporary volume but lack integrated channels to defend long-term share. Elevated distribution costs and front-loaded CapEx create a timing mismatch that will depress free cash flow near-term but steepen later-cycle cash conversion as volumes normalize — this amplifies upside to equity if operational milestones are met, but amplifies downside if share recovery stalls.

Key risks are binary and time-limited: a) a relapse in fulfillment (weeks–months) that resets customer re-contracting timelines, b) worsening U.S. animal-farm economics that prolongs distributor destocking (quarters), and c) slower-than-expected margin recovery from logistics. Monitoring high-frequency indicators (weekly fill rates, large distributor reorder cadence, Petrifilm reader adoption) will resolve the thesis well ahead of quarterly reporting cycles.

Key Decisions for Investors

• Conditional long NEOG (NEOG) — Scale in on two confirmed operational signals: (1) two consecutive quarters of sequential improvement in customer fill-rates and (2) gross-margin improvement ≥100 bps YoY. Entry: 50% position after first confirmation, add remaining 50% after second. Timeframe: 12–18 months. Risk/reward: stop-loss 18%; target 35–60% upside tied to share recapture and operating leverage.
• Asymmetric call exposure — Buy 12–24 month LEAP calls on NEOG (choose delta ~0.30–0.40 to balance premium vs upside). Rationale: caps cash at premium while capturing multi-quarter share-recapture upside; ideal if you expect operational improvement but want defined downside. Timeframe: 9–24 months. Risk/reward: max loss = premium; potential 3x+ return if share recapture and margin tailwinds materialize.
• Event-driven pair (risk-reduced) — Long NEOG / short QGEN equal notional (NEOG long vs QGEN short) as a hedge of sector-agnostic risk: go long NEOG to capture differentiated food-safety regulatory flow and share-recapture optionality, short QIAGEN to offset broader diagnostic-sector beta. Timeframe: 6–12 months. Risk/reward: reduces market direction risk; unwind if sector rotates or if NEOG fails to show operational progress after two quarters.
• Avoid leveraged credit exposure until deleveraging visibility improves — refrain from buying Neogen corporate credit or arranging large private credit positions until net leverage demonstrably falls below ~2.5x on a trailing-12-month basis; operational execution risk makes spread compression binary in the near term. Timeframe: review at each quarter report. Risk/reward: preserves capital against a failed recovery while retaining optionality to add on confirmed deleveraging.